The PAH treatment market is expected to grow from USD 5,811.5 million in 2023 to USD 7,224.4 million by 2033, at a CAGR of ...

The immune protein STAT6 may be a driver of pulmonary hypertension in people with obstructive sleep apnea, a study in mice ...

Akura Medical has enrolled the first subject in the multi-centre QUADRA-PE trial, which is assessing its flagship Katana ...

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...

Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, today ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

Eko Health developed an AI algorithm that, combined with noninvasive heart tests, may be able to accurately identify ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...